Sai Parenteral's Limited
ListedMainboardHealthcare · NSE / BSE
Incorporated in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical company engaged in the research, development, and manufacturing of formulations, operating across two main segments: branded generic formulations and contract development and manufacturing (CDMO) services for both domestic and international markets. Its product portfolio covers multiple therapeutic areas such as cardiovascular, neuropsychiatry, anti-diabetic, respiratory, antibiotics, gastroenterology, vitamins, minerals and supplements, analgesics, and dermatology, with offerings available in various dosage forms including injectables, tablets, capsules, liquid orals, and ointments. The company serves a wide customer base including government agencies, pharmaceutical companies, hospitals, and distributors across India, and expanded into exports in FY 2023 after acquiring internationally accredited facilities in Hyderabad, enabling supply to markets like Australia, New Zealand, Southeast Asia, the Middle East, and Africa. Sai Parenteral's operates five manufacturing facilities in India, four in Hyderabad and one through its wholly owned subsidiary Revat Laboratories in Ongole, Andhra Pradesh, all equipped with GMP and global certifications, and as of August 31, 2025, the company had 277 full-time employees.
Price Band
₹372 – ₹392
Issue Size
₹1042.83 L Cr
Lot Size
38 shares
GMP
—
Est. Listing
₹392
at current GMP
Subscribed
1.08x
overall
Open
24 Mar 2026
Close
27 Mar 2026
Allotment
30 Mar 2026
Refund
31 Mar 2026
Demat Credit
1 Apr 2026
Listing
2 Apr 2026
Last updated 6 months ago
Live Grey Market Premium
Sai Parenteral's Limited GMP Today
Last updated: 4 Apr 2026
Current Premium
₹00.0%
Issue Price (Upper)
₹392
Band: ₹372 – ₹392
Estimated Listing Price
₹392
Upper price + GMP
Lot Size
38 shares
Min investment ₹14,896
Estimated Profit / Lot
₹0
38 × ₹0
Sai Parenteral's Limited GMP Historical Trend
GMP History
Grey Market Premium trend
—
▲ 0 today
Updated 1 minute ago
Estimated Listing Price
| Date | GMP (₹) | GMP % | Est. Listing |
|---|---|---|---|
| 28 Sep 2026 | — | 0.0% | ₹392 |
| 26 Sep 2026 | — | 0.0% | ₹392 |
| 25 Sep 2026 | — | 0.0% | ₹392 |
GMP is unofficial market data. Not a guarantee of listing performance.
About Sai Parenteral's Limited Public Issue & Market Profile
Sai Parenteral's Limited is bringing an initial public offering (IPO) in the Healthcare sector with an aggregate issue size of ₹1,04,28,288 Crores. The shares are offered at a price band of ₹372 to ₹392 per equity share on NSE and BSE. Currently, traders and retail applicants are calculating expected listing gains and break-even points based on unofficial grey market quotations.
Public Issue & Pricing Context:
Prospective investors can apply in the retail quota with a minimum of 1 lot comprising 38 shares (approx. ₹14,896 minimum investment). High net-worth individuals (HNI/NII) can bid in the sHNI (₹2 Lakh to ₹10 Lakh) or bHNI (above ₹10 Lakh) categories for enhanced quota allocation.
Basis of Allotment & Listing Timeline:
Allotment reconciliation will be managed by Bigshare Services Private Limited. Eligible allottees will receive credit of equity shares into their Demat accounts by 2026-04-01, while un-allotted funds or UPI block mandates will be released on 2026-03-31.
Frequently Asked Questions
What is Sai Parenteral's Limited IPO GMP today?
The latest grey market premium for Sai Parenteral's Limited IPO is ₹0, which indicates an expected listing price of ₹392.
What does Kostak Rate and Sauda mean in IPO GMP?
Kostak rate is the profit amount an investor earns by selling their entire IPO application in the grey market before allotment is finalized.
Is Grey Market Premium officially recognized?
No. GMP is an unofficial indicator discovered between dealers outside of SEBI-regulated exchanges. Actual listing price is determined by demand-supply discovery on NSE/BSE during the pre-open auction.